CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
This article is part of the Research TopicReviews in Thoracic OncologyView all 12 articles
Complete Remission of Thymic Carcinoma Using Dose-Dense Chemotherapy
Provisionally accepted
- 1Indiana University Department of Medicine, Indianapolis, United States
- 2Indiana University School of Medicine, Indianapolis, United States
- 3Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract: Thymic epithelial tumors, including thymoma and thymic carcinoma, are rare malignancies of the mediastinum, often associated with poor long-term outcomes in advanced stages. Surgical resection and platinum-based chemotherapy have been the cornerstone of management for resectable and advanced, unresectable disease, respectively, with the use of neoadjuvant chemotherapy alone or chemotherapy combined with radiation in specific cases. We report the case of a patient diagnosed with advanced hormone receptor-positive/HER2-positive breast cancer and a synchronous, advanced thymic carcinoma. After completion of standard-of-care adjuvant dose-dense chemotherapy for her breast cancer, interval imaging revealed marked reduction in the size of the thymic mass with subsequent surgical resection noting a complete pathologic response. The patient remained disease-free for four years before developing recurrence of the thymic carcinoma. This case highlights the potential effectiveness of dose-dense chemotherapy in the treatment of thymic malignancies. Locally advanced and metastatic thymic carcinoma remains challenging to manage, making this patient's response particularly noteworthy. Given that the therapeutic strategies for thymic tumors have remained largely unchanged in recent years, dose-dense chemotherapy may represent a promising addition to the current treatment paradigm, though further investigation is needed to evaluate its broader applicability.
Keywords: breast cancer, case report, Dose-dense chemotherapy, Neoadjuvant Therapy, Thymic carcinoma
Received: 26 Oct 2025; Accepted: 12 Feb 2026.
Copyright: © 2026 Shu, Hou, Rissing, Maniar and Loehrer, Sr.. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mae Shu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.